A 52-year-old woman with type 2 diabetes presents with velvety, hyperpigmented plaques on the neck and axillae. Her sister, also diabetic, has similar skin changes but additionally reports progressive hair loss on the scalp. Which clinical feature best distinguishes acanthosis nigricans associated with insulin resistance from that associated with an underlying malignancy?

Explanation

## Distinguishing Benign (Metabolic) from Malignant Acanthosis Nigricans ### Key Clinical Differences **Key Point:** Acanthosis nigricans associated with insulin resistance (benign form) presents with symmetrical, slow-onset lesions linked to obesity and metabolic dysfunction, whereas malignancy-associated acanthosis nigricans (MANL) is rapid, aggressive, and accompanied by systemic B symptoms and constitutional signs. ### Comparison Table | Feature | Insulin Resistance–Associated | Malignancy-Associated | |---------|-------------------------------|----------------------| | **Onset** | Insidious, years | Rapid, weeks to months | | **Distribution** | Symmetrical, intertriginous | Often extensive, may be atypical | | **Associated findings** | Metabolic syndrome, obesity, PCOS | Weight loss, fever, night sweats | | **Prognosis** | Stable, improves with weight loss | Progressive, poor prognosis | | **Prevalence** | 90% of AN cases | 10% of AN cases | | **Associated malignancy** | None | Gastric (most common), lung, breast | ### Why Option 3 Is Correct **High-Yield:** The hallmark of benign (metabolic) acanthosis nigricans is its **symmetrical distribution**, **slow insidious onset**, and **strong association with insulin resistance and metabolic syndrome** (obesity, type 2 diabetes, PCOS, dyslipidemia). Systemic symptoms are absent. This contrasts sharply with malignancy-associated forms, which present acutely with constitutional symptoms. **Clinical Pearl:** In a patient with diabetes and metabolic syndrome presenting with symmetrical, velvety hyperpigmentation in classic intertriginous sites (neck, axillae, groin, inframammary), malignancy screening is not routinely indicated unless red flags (rapid onset, weight loss, atypical distribution) are present. ### Why Each Distractor Is Wrong 1. **Option 0 (Presence of associated alopecia):** Alopecia and hair thinning can occur in both metabolic and malignant forms due to shared endocrine dysfunction (hyperandrogenism, thyroid disease). This is not a discriminating feature. The sister's hair loss reflects PCOS or metabolic dysregulation, not malignancy. 2. **Option 1 (Rapid onset over weeks to months):** While rapid onset *favours* malignancy, it is not specific to malignancy-associated AN. Rapid worsening can also occur with acute metabolic decompensation or sudden weight gain. The question asks for the **best discriminating feature**, and rapid onset alone is insufficient without systemic context. 3. **Option 2 (Involvement limited to intertriginous areas):** Both benign and malignant forms can involve intertriginous areas. Malignancy-associated AN may extend beyond flexural sites, but limitation to intertriginous areas does not exclude malignancy. This is not a reliable discriminator.